These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
655 related articles for article (PubMed ID: 15944649)
1. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. Price JC; Klunk WE; Lopresti BJ; Lu X; Hoge JA; Ziolko SK; Holt DP; Meltzer CC; DeKosky ST; Mathis CA J Cereb Blood Flow Metab; 2005 Nov; 25(11):1528-47. PubMed ID: 15944649 [TBL] [Abstract][Full Text] [Related]
2. Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. Lopresti BJ; Klunk WE; Mathis CA; Hoge JA; Ziolko SK; Lu X; Meltzer CC; Schimmel K; Tsopelas ND; DeKosky ST; Price JC J Nucl Med; 2005 Dec; 46(12):1959-72. PubMed ID: 16330558 [TBL] [Abstract][Full Text] [Related]
3. Using a reference tissue model with spatial constraint to quantify [11C]Pittsburgh compound B PET for early diagnosis of Alzheimer's disease. Zhou Y; Resnick SM; Ye W; Fan H; Holt DP; Klunk WE; Mathis CA; Dannals R; Wong DF Neuroimage; 2007 Jun; 36(2):298-312. PubMed ID: 17449282 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of voxel-based methods for the statistical analysis of PIB PET amyloid imaging studies in Alzheimer's disease. Ziolko SK; Weissfeld LA; Klunk WE; Mathis CA; Hoge JA; Lopresti BJ; DeKosky ST; Price JC Neuroimage; 2006 Oct; 33(1):94-102. PubMed ID: 16905334 [TBL] [Abstract][Full Text] [Related]
5. Comparison of MRI based and PET template based approaches in the quantitative analysis of amyloid imaging with PIB-PET. Edison P; Carter SF; Rinne JO; Gelosa G; Herholz K; Nordberg A; Brooks DJ; Hinz R Neuroimage; 2013 Apr; 70():423-33. PubMed ID: 23261639 [TBL] [Abstract][Full Text] [Related]
6. Relative 11C-PiB Delivery as a Proxy of Relative CBF: Quantitative Evaluation Using Single-Session 15O-Water and 11C-PiB PET. Chen YJ; Rosario BL; Mowrey W; Laymon CM; Lu X; Lopez OL; Klunk WE; Lopresti BJ; Mathis CA; Price JC J Nucl Med; 2015 Aug; 56(8):1199-205. PubMed ID: 26045309 [TBL] [Abstract][Full Text] [Related]
7. Clinically different stages of Alzheimer's disease associated by amyloid deposition with [11C]-PIB PET imaging. Hatashita S; Yamasaki H J Alzheimers Dis; 2010; 21(3):995-1003. PubMed ID: 20693641 [TBL] [Abstract][Full Text] [Related]
8. Consideration of optimal time window for Pittsburgh compound B PET summed uptake measurements. McNamee RL; Yee SH; Price JC; Klunk WE; Rosario B; Weissfeld L; Ziolko S; Berginc M; Lopresti B; Dekosky S; Mathis CA J Nucl Med; 2009 Mar; 50(3):348-55. PubMed ID: 19223409 [TBL] [Abstract][Full Text] [Related]
9. Tracer Kinetic Analysis of (S)-¹⁸F-THK5117 as a PET Tracer for Assessing Tau Pathology. Jonasson M; Wall A; Chiotis K; Saint-Aubert L; Wilking H; Sprycha M; Borg B; Thibblin A; Eriksson J; Sörensen J; Antoni G; Nordberg A; Lubberink M J Nucl Med; 2016 Apr; 57(4):574-81. PubMed ID: 26795290 [TBL] [Abstract][Full Text] [Related]
10. Comparison of qualitative and quantitative imaging characteristics of [11C]PiB and [18F]flutemetamol in normal control and Alzheimer's subjects. Mountz JM; Laymon CM; Cohen AD; Zhang Z; Price JC; Boudhar S; McDade E; Aizenstein HJ; Klunk WE; Mathis CA Neuroimage Clin; 2015; 9():592-8. PubMed ID: 26640770 [TBL] [Abstract][Full Text] [Related]
11. Voxel-based analysis of Alzheimer's disease PET imaging using a triplet of radiotracers: PIB, FDDNP, and FDG. Shin J; Lee SY; Kim SJ; Kim SH; Cho SJ; Kim YB Neuroimage; 2010 Aug; 52(2):488-96. PubMed ID: 20385246 [TBL] [Abstract][Full Text] [Related]
13. Dual-biomarker imaging of regional cerebral amyloid load and neuronal activity in dementia with PET and 11C-labeled Pittsburgh compound B. Meyer PT; Hellwig S; Amtage F; Rottenburger C; Sahm U; Reuland P; Weber WA; Hüll M J Nucl Med; 2011 Mar; 52(3):393-400. PubMed ID: 21321269 [TBL] [Abstract][Full Text] [Related]
14. Can target-to-pons ratio be used as a reliable method for the analysis of [11C]PIB brain scans? Edison P; Hinz R; Ramlackhansingh A; Thomas J; Gelosa G; Archer HA; Turkheimer FE; Brooks DJ Neuroimage; 2012 Apr; 60(3):1716-23. PubMed ID: 22306804 [TBL] [Abstract][Full Text] [Related]
15. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Klunk WE; Engler H; Nordberg A; Wang Y; Blomqvist G; Holt DP; Bergström M; Savitcheva I; Huang GF; Estrada S; Ausén B; Debnath ML; Barletta J; Price JC; Sandell J; Lopresti BJ; Wall A; Koivisto P; Antoni G; Mathis CA; Långström B Ann Neurol; 2004 Mar; 55(3):306-19. PubMed ID: 14991808 [TBL] [Abstract][Full Text] [Related]
16. Characterizing regional correlation, laterality and symmetry of amyloid deposition in mild cognitive impairment and Alzheimer's disease with Pittsburgh Compound B. Raji CA; Becker JT; Tsopelas ND; Price JC; Mathis CA; Saxton JA; Lopresti BJ; Hoge JA; Ziolko SK; DeKosky ST; Klunk WE J Neurosci Methods; 2008 Jul; 172(2):277-82. PubMed ID: 18582948 [TBL] [Abstract][Full Text] [Related]
17. [18F]Flutemetamol amyloid-beta PET imaging compared with [11C]PIB across the spectrum of Alzheimer's disease. Hatashita S; Yamasaki H; Suzuki Y; Tanaka K; Wakebe D; Hayakawa H Eur J Nucl Med Mol Imaging; 2014 Feb; 41(2):290-300. PubMed ID: 24085503 [TBL] [Abstract][Full Text] [Related]
18. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Jack CR; Lowe VJ; Senjem ML; Weigand SD; Kemp BJ; Shiung MM; Knopman DS; Boeve BF; Klunk WE; Mathis CA; Petersen RC Brain; 2008 Mar; 131(Pt 3):665-80. PubMed ID: 18263627 [TBL] [Abstract][Full Text] [Related]
19. Amyloid-β Deposition and Long-Term Progression in Mild Cognitive Impairment due to Alzheimer's Disease Defined with Amyloid PET Imaging. Hatashita S; Wakebe D J Alzheimers Dis; 2017; 57(3):765-773. PubMed ID: 28304292 [TBL] [Abstract][Full Text] [Related]